Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ch14.18 in High Risk Neuroblastoma Following ASCT
NCT00026312Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2001
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of dinutuximab in neuroblastoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Event-Free Survival at 3 years. Started Oct 2001; status: completed.
02
Drugs
dinutuximab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00026312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026312.